Publications by authors named "April Teitelbaum"

Claim this Profile
H
Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims study.
Lincy S Lal, Abdalla Aly, Lisa B Le, Susan Peckous, Brian Seal, April Teitelbaum

Cancer Rep (Hoboken)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database.
Tanya Burton, Stacey DaCosta Byfield, Gregory L Smith, Giovanni Zanotti, Timothy J Bell, April Teitelbaum

Curr Med Res Opin· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Evaluation of Algorithms for Identifying Metastatic Breast, Lung, or Colorectal Cancer in Administrative Claims Data.
Joanna L Whyte, Nicole M Engel-Nitz, April Teitelbaum, Gabriel Gomez Rey, Joel D Kallich

Med Care· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab.
Anju Parthan, Eduardo Santos, Laura Becker, Arthur Small, Deepa Lalla, April Teitelbaum

J Manag Care Spec Pharm· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic testing managed by hematopathology specialty and other laboratories: costs and patient diagnostic outcomes.
Nicole M Engel-Nitz, Benjamin Eckert, Rui Song, Priyanka Koka, Erin M Hulbert, April Teitelbaum

BMC Clin Pathol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population.
Stacey DaCosta Byfield, Emily Nash Smyth, Daniel Mytelka, Lee Bowman, April Teitelbaum

J Med Econ· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancer.
Saurabh Ray, Stacey Dacosta-Byfield, Arijit Ganguli, Vijayveer Bonthapally, April Teitelbaum

J Neurooncol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corroboration of claims algorithm for second-line costs of metastatic colorectal cancer treatment with targeted agents.
Stacey Dacosta Byfield, Elaine Yu, Robert Morlock, Dana Evans, April Teitelbaum

J Med Econ· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.
April Teitelbaum, Abbie Ba-Mancini, Hui Huang, Henry J Henk

Oncologist· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective claims analysis of best supportive care costs and survival in a US metastatic renal cell population.
Henry J Henk, Connie Chen, Agnes Benedict, Jane Sullivan, April Teitelbaum

Clinicoecon Outcomes Res· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs.
Carolina Reyes, Stacey DaCosta Byfield, Rolf Linke, Sacha Satram-Hoang, April H Teitelbaum

Melanoma Res· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health care costs for patients with cancer at the end of life.
Benjamin Chastek, Carolyn Harley, Joel Kallich, Lee Newcomer, Carly J Paoli, April H Teitelbaum

J Oncol Pract· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid.
Henry Henk, April Teitelbaum, Satyin Kaura

Curr Med Res Opin· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases.
Henry J Henk, Satyin Kaura, April Teitelbaum

J Med Econ· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma.
Henry J Henk, April Teitelbaum, Jose Ricardo Perez, Satyin Kaura

Am J Hematol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry.
Onur Baser, Wenhui Wei, Henry J Henk, April Teitelbaum, Lin Xie

Curr Med Res Opin· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population.
Mayur M Amonkar, Benjamin Chastek, Navendu Samant, April Teitelbaum

J Med Econ· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population.
Amin Haiderali, Laura Menditto, Margaret Good, April Teitelbaum, Jessica Wegner

Support Care Cancer· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis